Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1993 Apr;108(4):1051–1054. doi: 10.1111/j.1476-5381.1993.tb13504.x

Characterization of the inhibitory prostanoid receptors on human neutrophils.

A Wheeldon 1, C J Vardey 1
PMCID: PMC1908142  PMID: 8387383

Abstract

1. We have evaluated the effects of various prostanoid agonists on the release of leukotriene B4 (LTB4) and superoxide anions (O2-) from human neutrophils stimulated with opsonized zymosan (OZ) and formyl-methionyl-leucyl-phenylalanine (FMLP), respectively. 2. Prostaglandin E2 (PGE2) and PGD2 inhibited both OZ-induced LTB4 release (EC50 0.72 microM and 0.91 microM respectively), and FMLP-induced O2- release (EC50 0.42 microM and 0.50 microM respectively). PGF2 alpha, the TP-receptor agonist, U46619, and the IP-receptor agonist, iloprost, were also active, but were all at least an order of magnitude less potent than PGE2 and PGD2. 3. The EP2/EP3-receptor agonist, misoprostol, and the selective EP2-agonist, AH13205, were both effective inhibitors of LTB4 release, being approximately equipotent with and 16-times less potent than PGE2, respectively. In contrast, the EP1/EP3-receptor agonist, sulprostone, had no inhibitory activity at concentrations of up to 10 microM. 4. The selective DP-receptor agonist, BW245C, inhibited LTB4 release, (EC50 0.006 microM) being approximately 50 times more potent than PGD2. BW245C also inhibited O2- release, and this inhibition was antagonized competitively by the DP-receptor blocking drug, AH6809 (pA2 6.6). 5. These data indicate the presence of both inhibitory EP- and DP-receptors on the human neutrophil. The rank order of potency of EP-receptor agonists suggest that the EP-receptors are of the EP2-subtype.

Full text

PDF
1051

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Butchers P. R., Vardey C. J. The effect of prostanoids on the function of human eosinophils. Agents Actions Suppl. 1990;31:103–112. doi: 10.1007/978-3-0348-7379-6_12. [DOI] [PubMed] [Google Scholar]
  3. Fantone J. C., Kunkel S. L., Ward P. A. Suppression of human polymorphonuclear function after intravenous infusion of prostaglandin E1. Prostaglandins Med. 1981 Aug;7(2):195–198. doi: 10.1016/0161-4630(81)90062-8. [DOI] [PubMed] [Google Scholar]
  4. Gemsa D., Leser H. G., Seitz M., Deimann W., Bärlin E. Membrane perturbation and stimulation of arachidonic acid metabolism. Mol Immunol. 1982 Oct;19(10):1287–1296. doi: 10.1016/0161-5890(82)90295-4. [DOI] [PubMed] [Google Scholar]
  5. Grundemar L., Jonas S. E., Mörner N., Högestätt E. D., Wahlestedt C., Håkanson R. Characterization of vascular neuropeptide Y receptors. Br J Pharmacol. 1992 Jan;105(1):45–50. doi: 10.1111/j.1476-5381.1992.tb14208.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gryglewski R. J., Szczeklik A., Wandzilak M. The effect of six prostaglandins, prostacyclin and iloprost on generation of superoxide anions by human polymorphonuclear leukocytes stimulated by zymosan or formyl-methionyl-leucyl-phenylalanine. Biochem Pharmacol. 1987 Dec 15;36(24):4209–4213. doi: 10.1016/0006-2952(87)90660-5. [DOI] [PubMed] [Google Scholar]
  7. Ham E. A., Soderman D. D., Zanetti M. E., Dougherty H. W., McCauley E., Kuehl F. A., Jr Inhibition by prostaglandins of leukotriene B4 release from activated neutrophils. Proc Natl Acad Sci U S A. 1983 Jul;80(14):4349–4353. doi: 10.1073/pnas.80.14.4349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Heavey D. J., Lumley P., Barrow S. E., Murphy M. B., Humphrey P. P., Dollery C. T. Effects of intravenous infusions of prostaglandin D2 in man. Prostaglandins. 1984 Dec;28(6):755–767. doi: 10.1016/0090-6980(84)90033-9. [DOI] [PubMed] [Google Scholar]
  9. Holcroft J. W., Vassar M. J., Weber C. J. Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome. A prospective trial. Ann Surg. 1986 Apr;203(4):371–378. doi: 10.1097/00000658-198604000-00006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Keery R. J., Lumley P. AH6809, a prostaglandin DP-receptor blocking drug on human platelets. Br J Pharmacol. 1988 Jul;94(3):745–754. doi: 10.1111/j.1476-5381.1988.tb11584.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kunkel S. L., Thrall R. S., Kunkel R. G., McCormick J. R., Ward P. A., Zurier R. B. Suppression of immune complex vasculitis in rats by prostaglandin. J Clin Invest. 1979 Nov;64(5):1525–1529. doi: 10.1172/JCI109611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lad P. M., Goldberg B. J., Smiley P. A., Olson C. V. Receptor-specific threshold effects of cyclic AMP are involved in the regulation of enzyme release and superoxide production from human neutrophils. Biochim Biophys Acta. 1985 Aug 30;846(2):286–295. doi: 10.1016/0167-4889(85)90076-x. [DOI] [PubMed] [Google Scholar]
  13. Lewis R. A., Holgate S. T., Roberts L. J., 2nd, Oates J. A., Austen K. F. Preferential generation of prostaglandin D2 by rat and human mast cells. Kroc Found Ser. 1981;14:239–254. [PubMed] [Google Scholar]
  14. McGuire J. C., Sun F. F. Metabolism of arachidonic acid and prostaglandin endoperoxide by assorted leukocytes. Adv Prostaglandin Thromboxane Res. 1980;8:1665–1667. [PubMed] [Google Scholar]
  15. Ney P., Schrör K. PGD2 and its mimetic ZK 110.841 are potent inhibitors of receptor-mediated activation of human neutrophils. Eicosanoids. 1991;4(1):21–28. [PubMed] [Google Scholar]
  16. Olsson I., Venge P. The role of the human neutrophil in the inflammatory reaction. Allergy. 1980 Jan;35(1):1–13. doi: 10.1111/j.1398-9995.1980.tb01711.x. [DOI] [PubMed] [Google Scholar]
  17. Orchard M. A., Ritter J. M., Shepherd G. L., Lewis P. J. Cardiovascular and platelet effects in man of BW 245C, a stable mimic of epoprostenol (PGI2). Br J Clin Pharmacol. 1983 May;15(5):509–511. doi: 10.1111/j.1365-2125.1983.tb02083.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Peters S. P., MacGlashan D. W., Jr, Schulman E. S., Schleimer R. P., Hayes E. C., Rokach J., Adkinson N. F., Jr, Lichtenstein L. M. Arachidonic acid metabolism in purified human lung mast cells. J Immunol. 1984 Apr;132(4):1972–1979. [PubMed] [Google Scholar]
  19. Schmeichel C. J., Thomas L. L. Methylxanthine bronchodilators potentiate multiple human neutrophil functions. J Immunol. 1987 Mar 15;138(6):1896–1903. [PubMed] [Google Scholar]
  20. Zurier R. B., Quagliata F. Effect of prostaglandin E 1 on adjuvant arthritis. Nature. 1971 Dec 3;234(5327):304–305. doi: 10.1038/234304a0. [DOI] [PubMed] [Google Scholar]
  21. Zurier R. B., Weissmann G., Hoffstein S., Kammerman S., Tai H. H. Mechanisms of lysosomal enzyme release from human leukocytes. II. Effects of cAMP and cGMP, autonomic agonists, and agents which affect microtubule function. J Clin Invest. 1974 Jan;53(1):297–309. doi: 10.1172/JCI107550. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES